Demographic, clinical, and epidemiologic characteristics of persons under investigation for Coronavirus Disease 2019—United States, January 17–February 29, 2020 | Zendy

Olivia L. McGovern | Zendy; Mark Stenger | Zendy; Sara E. Oliver | Zendy; Tara C. Anderson | Zendy; Cheryl Isenhour | Zendy; Matthew R. Mauldin | Zendy; Nia Williams | Zendy; Eric P. Griggs | Zendy; Tonny Bogere | Zendy; Chris Edens | Zendy; Aaron T. Curns | Zendy; Joana Y Lively | Zendy; Yingtao Zhou | Zendy; Songli Xu | Zendy; Maureen H. Diaz | Zendy; Jessica L. Waller | Zendy; Kevin R. Clarke | Zendy; Mary E. Evans | Zendy; Elisabeth M. Hesse | Zendy; Sapna Bamrah Morris | Zendy; R. Paul McClung | Zendy; Laura A. Cooley | Zendy; Naeemah Logan | Zendy; Andrew T. Boyd | Zendy; Allan W. Taylor | Zendy; Kristina L. Bajema | Zendy; Stephen Lindstrom | Zendy; Christopher A. Elkins | Zendy; Christopher B Jones | Zendy; Aron J. Hall | Zendy; Samuel B. Graitcer | Zendy; Alexandra M. Oster | Zendy; Alicia M. Fry | Zendy; Marc Fischer | Zendy; Laura Conklin | Zendy; Runa H. Gokhale | Zendy

Open Access

Demographic, clinical, and epidemiologic characteristics of persons under investigation for Coronavirus Disease 2019—United States, January 17–February 29, 2020

Author(s) -

Olivia L. McGovern,

Mark Stenger,

Sara E. Oliver,

Tara C. Anderson,

Cheryl Isenhour,

Matthew R. Mauldin,

Nia Williams,

Eric P. Griggs,

Tonny Bogere,

Chris Edens,

Aaron T. Curns,

Joana Y Lively,

Yingtao Zhou,

Songli Xu,

Maureen H. Diaz,

Jessica L. Waller,

Kevin R. Clarke,

Mary E. Evans,

Elisabeth M. Hesse,

Sapna Bamrah Morris,

R. Paul McClung,

Laura A. Cooley,

Naeemah Logan,

Andrew T. Boyd,

Allan W. Taylor,

Kristina L. Bajema,

Stephen Lindstrom,

Christopher A. Elkins,

Christopher B Jones,

Aron J. Hall,

Samuel B. Graitcer,

Alexandra M. Oster,

Alicia M. Fry,

Marc Fischer,

Laura Conklin,

Runa H. Gokhale

Publication year - 2021

Publication title -

plos one

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.99

H-Index - 332

ISSN - 1932-6203

DOI - 10.1371/journal.pone.0249901

Subject(s) - pandemic , preparedness , medicine , public health , covid-19 , epidemiology , public health surveillance , disease , disease control , health care , family medicine , environmental health , infectious disease (medical specialty) , pathology , political science , law , economics , economic growth

Background The Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), evolved rapidly in the United States. This report describes the demographic, clinical, and epidemiologic characteristics of 544 U.S. persons under investigation (PUI) for COVID-19 with complete SARS-CoV-2 testing in the beginning stages of the pandemic from January 17 through February 29, 2020. Methods In this surveillance cohort, the U.S. Centers for Disease Control and Prevention (CDC) provided consultation to public health and healthcare professionals to identify PUI for SARS-CoV-2 testing by quantitative real-time reverse-transcription PCR. Demographic, clinical, and epidemiologic characteristics of PUI were reported by public health and healthcare professionals during consultation with on-call CDC clinicians and subsequent submission of a CDC PUI Report Form. Characteristics of laboratory-negative and laboratory-positive persons were summarized as proportions for the period of January 17−February 29, and characteristics of all PUI were compared before and after February 12 using prevalence ratios. Results A total of 36 PUI tested positive for SARS-CoV-2 and were classified as confirmed cases. Confirmed cases and PUI testing negative for SARS-CoV-2 had similar demographic, clinical, and epidemiologic characteristics. Consistent with changes in PUI evaluation criteria, 88% (13/15) of confirmed cases detected before February 12, 2020, reported travel from China. After February 12, 57% (12/21) of confirmed cases reported no known travel- or contact-related exposures. Conclusions These findings can inform preparedness for future pandemics, including capacity for rapid expansion of novel diagnostic tests to accommodate broad surveillance strategies to assess community transmission, including potential contributions from asymptomatic and presymptomatic infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research